Neurology

Serotonin syndrome generally occurs within 6 hours of a change in dose or addition of medication.

Researchers also noted the importance of patient-reported outcomes due to the fluctuating and unpredictable nature of generalized myasthenia gravis and the subjectivity of symptoms.

Ravulizumab-cwvz (Ultomiris) is the first and only long-acting C5 complement inhibitor for the treatment of generalized myasthenia gravis to gain FDA approval.

Fremanezumab is the second FDA-approved preventive migraine treatment that blocks the activity of calcitonin gene-related peptide.

Conditions such as high blood pressure, diabetes, and obesity may have a significant impact on the likelihood of developing cognitive decline, dementia, and Alzheimer disease.

New analysis demonstrates that physical activity improves cognitive health, thus staving off dementia.

Fosdenopterin (Nulibry) is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency Type A.

Haloperidol (Haldol) is indicated for use in the treatment of schizophrenia and to control the symptoms of Tourette's disorder, as well as severe behavioral problems or hyperactivity in children.

Eptinezumab is a calcitonin gene-related peptide antagonist FDA-approved for the preventive treatment of migraine.

Dhivy is a levodopa/carbidopa combination formulation approved by the FDA in November 2021 for the treatment of Parkinson disease or manifestations due to viral or environmental exposures.

Ponesimod (Ponvory) is indicated for the treatment of relapsing forms of multiple sclerosis.

Pharmacists should review the medications of patients with multiple sclerosis regularly to assess drug-drug interactions.

Ravulizumab-cwvz (Ultomiris) produced statistically significant improvements in measures of functional activity, muscle strength, and quality of life in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

Pharmacists who educate patients with multiple sclerosis and expand their understanding and knowledge of the condition empowers them to take part in a more active role in managing their health.

Valbenazine (Ingrezza) is indicated for the treatment of adults with tardive dyskinesia.

New validated testing method for multiple sclerosis measures kappa immunoglobulin free light chains in cerebrospinal fluid.

Namzaric is indicated for the treatment of moderate to severe dementia related to Alzheimer disease.

Donepezil (Aricept) is an acetylcholinesterase inhibitor indicated for the treatment of dementia related to Alzheimer disease.

Phase 3 trial results also indicate that Alzheimer disease clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks.

Corium’s Adlarity system lowers the likelihood of adverse gastrointestinal (GI) events that are normally associated with the oral medication.

Individuals with multiple sclerosis should follow vaccine guidelines before starting disease-modifying therapies, case study results show.

Michael Abrams, MPH, PhD, senior health researcher at Public Citizen’s Health Research Group, discusses whether classification of gabapentin as schedule V would end patients’ access to the drug.

Pharmacists hold a vastly underrecognized role within the care team—a role that offers a unique approach toward the therapeutic management of rare diseases.

Diroximel fumarate (Vumerity) is indicated for the treatment of relapsing forms of multiple sclerosis.

The agency has also approved the baclofen oral suspension for Azurity Pharmaceuticals to treat individuals with other spinal cord diseases or injuries.